Professional Statements and Societal Positions Guidelines
National Comprehensive Cancer Network (NCCN) – 2021
Indications for Allogeneic HCT for CLL/SLL (v.1.2022)
Allogeneic HCT can be considered for CLL/SLL refractory to small-molecule inhibitor therapy in [individuals] without significant comorbidities. HCT-specific comorbidity index (HCT-Cl) could be used for the assessment of comorbidities prior to HCT and to predict the risks of non-relapse mortality and the probabilities of survival after HCT.
For individuals with CLL/SLL with del(17p) or TP53 mutation, a discussion of allogeneic HCT could be considered for [individuals] in remission with or after ibrutinib therapy, if CK (greater than or equal to 3 abnormalities) is present. However, available data suggests that CK (greater than or equal to 5 abnormalities) is associated with inferior overall survival and EFS following allogeneic HCT with reduced-intensity conditioning in [individuals] with high-risk interphase cytogenetics.